Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The drug is priced at Rs 2000 for a course of 40 tablets
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The transaction is expected to close in the first quarter of 2022
The brand is now available pan-India through their distribution partner
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
It is the generic version of molnupiravir
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
